<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206618</url>
  </required_header>
  <id_info>
    <org_study_id>MYOBONE</org_study_id>
    <nct_id>NCT04206618</nct_id>
  </id_info>
  <brief_title>Circulating Myokine Levels and Bone Metabolism</brief_title>
  <official_title>The Role of Myokines in Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>424 General Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>424 General Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circulating levels of several myokines will be measured in serum samples obtained from women
      in various categories of bone density and according to the presence of fracture or not as
      well as before and after treatment with teriparatide and denosumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum samples for the measurement of several myokines will be obtained from: 1) equal groups
      of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal
      women with osteopenia, and postmenopausal women with osteoporosis; 2) women with hip fracture
      compared with controls (women subjected to surgery due to knee osteoathritis); 3) women with
      osteoporosis treated with teriparatide or denosumab for 12 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>follistatin</measure>
    <time_frame>0,3,12 months</time_frame>
    <description>circulating levels of myokine follistatin at baseline and their changes at 3 and 12 months with treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>activin-A</measure>
    <time_frame>0,3,12 months</time_frame>
    <description>circulating levels of myokine activin-A at baseline and their changes at 3 and 12 months with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSTL3</measure>
    <time_frame>0,3,12 months</time_frame>
    <description>circulating levels of myokine FSTL3 at baseline and their changes at 3 and 12 months with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activin-B</measure>
    <time_frame>0,3,12 months</time_frame>
    <description>circulating levels of activin-B at baseline and their changes at 3 and 12 months with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irisin</measure>
    <time_frame>0,3,12 months</time_frame>
    <description>circulating levels of myokine irisin at baseline and their changes at 3 and 12 months with treatment</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>premenopausal normal</arm_group_label>
    <description>premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postmenopausal normal</arm_group_label>
    <description>postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postmenopausal osteopenia</arm_group_label>
    <description>postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postmenopausal osteoporosis</arm_group_label>
    <description>postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hip fracture</arm_group_label>
    <description>postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls (knee osteoarthitis)</arm_group_label>
    <description>postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide group</arm_group_label>
    <description>postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>denosumab group</arm_group_label>
    <description>postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>1 subcutaneous injection daily for 12 months</description>
    <arm_group_label>teriparatide group</arm_group_label>
    <other_name>rhPTH 1-34</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>1 subcutaneous injection every 6 months for 12 months</description>
    <arm_group_label>denosumab group</arm_group_label>
    <other_name>RANKL inhibitor</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Substudy 1: equal groups (n=25) of premenopausal women with normal BMD, postmenopausal
        women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with
        osteoporosis Substudy 2: postmenopausal women with an incident hip fracture (n=40) compared
        with controls (postmenopausal women with knee osteoarhtritis) Substudy 3: postmenopausal
        women with osteoporosis will receive treatment with either teriparatide or denosumab for 12
        months
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Substudy 1:

        • adult women

        Substudy 2:

        • postmenopausal women with an incident hip fracture

        Substudy 3:

        • postmenopausal women with osteoporosis

        Exclusion Criteria:

          -  secondary osteoporosis

          -  any disease that could affect muscle and/or bone metabolism

          -  any medication that could affect muscle and/or bone metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanasios Anastasilakis, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>424 General Military Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athanasios Anastasilakis, PhD</last_name>
    <phone>+302310381000</phone>
    <phone_ext>1069</phone_ext>
    <email>a.anastasilakis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stylianos Mandanas, MD</last_name>
    <phone>+302310381000</phone>
    <phone_ext>1092</phone_ext>
    <email>smandanas@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>424 General Military Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <state>Northern Greece</state>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Anastasilakis, PhD</last_name>
      <phone>+302310381000</phone>
      <phone_ext>1069</phone_ext>
      <email>a.anastasilakis@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stylianos Mandanas, MD</last_name>
      <phone>+302310381000</phone>
      <phone_ext>1092</phone_ext>
      <email>smandanas@yahoo.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Bowser M, Herberg S, Arounleut P, Shi X, Fulzele S, Hill WD, Isales CM, Hamrick MW. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol. 2013 Feb;48(2):290-7. doi: 10.1016/j.exger.2012.11.004. Epub 2012 Nov 21.</citation>
    <PMID>23178301</PMID>
  </reference>
  <reference>
    <citation>Lotinun S, Pearsall RS, Horne WC, Baron R. Activin receptor signaling: a potential therapeutic target for osteoporosis. Curr Mol Pharmacol. 2012 Jun;5(2):195-204. Review.</citation>
    <PMID>21787285</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Savvides M, Papatheodorou A, Terpos E. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporos Int. 2013 Jul;24(7):2127-32. doi: 10.1007/s00198-012-2198-0. Epub 2012 Nov 3.</citation>
    <PMID>23124716</PMID>
  </reference>
  <reference>
    <citation>Lodberg A, Eijken M, van der Eerden BCJ, Okkels MW, Thomsen JS, Brüel A. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia. Bone. 2018 May;110:326-334. doi: 10.1016/j.bone.2018.02.026. Epub 2018 Feb 28.</citation>
    <PMID>29499419</PMID>
  </reference>
  <reference>
    <citation>Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010 Apr;46(4):1082-8. doi: 10.1016/j.bone.2010.01.370. Epub 2010 Jan 18.</citation>
    <PMID>20080223</PMID>
  </reference>
  <reference>
    <citation>Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009 Apr;24(4):744-52. doi: 10.1359/jbmr.081208.</citation>
    <PMID>19049340</PMID>
  </reference>
  <reference>
    <citation>Fahmy-Garcia S, Farrell E, Witte-Bouma J, Robbesom-van den Berge I, Suarez M, Mumcuoglu D, Walles H, Kluijtmans SGJM, van der Eerden BCJ, van Osch GJVM, van Leeuwen JPTM, van Driel M. Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo. Front Bioeng Biotechnol. 2019 Mar 1;7:38. doi: 10.3389/fbioe.2019.00038. eCollection 2019.</citation>
    <PMID>30881954</PMID>
  </reference>
  <reference>
    <citation>Lodberg A, van der Eerden BCJ, Boers-Sijmons B, Thomsen JS, Brüel A, van Leeuwen JPTM, Eijken M. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice. FASEB J. 2019 May;33(5):6001-6010. doi: 10.1096/fj.201801969RR. Epub 2019 Feb 13.</citation>
    <PMID>30759349</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>424 General Military Hospital</investigator_affiliation>
    <investigator_full_name>Athanasios D. Anastasilakis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will become available after study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

